955-15-7

Usage

InChI:InChI=1/C11H13N3O2S/c1-8-7-9(2)14(13-8)10-3-5-11(6-4-10)17(12,15)16/h3-7H,1-2H3,(H2,12,15,16)

Upstream product

• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 
• 123-54-6 acetylacetone 

Downstream Products

• 1448798-87-5 N-[(dimethylamino)methylidene]-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzenesulfonamide 
• 79222-86-9 1-[4-(3,5-Dimethyl-pyrazol-1-yl)-benzenesulfonyl]-5-methyl-3-propyl-2-thioxo-imidazolidin-4-one 
• 69180-80-9 N-(cyclohexyl-thiocarbamoyl)-4-(3,5-dimethyl-pyrazol-1-yl)-benzenesulfonamide 
• 69180-77-4 N-(allyl-thiocarbamoyl)-4-(3,5-dimethyl-pyrazol-1-yl)-benzenesulfonamide 
• 69180-78-5 4-(3,5-dimethyl-pyrazol-1-yl)-N-(propyl-thiocarbamoyl)-benzenesulfonamide 
• 69180-81-0 N-(benzyl-thiocarbamoyl)-4-(3,5-dimethyl-pyrazol-1-yl)-benzenesulfonamide 

Relevant academic research and scientific papers

Inhibition of carbonic anhydrase II by sulfonamide derivatives

A series of sulfonamide derivatives were synthesized, and the enzyme inhibitory activity of the synthesized compounds on carbonic anhydrase II was evaluated. Through molecular docking studies, it was found that compounds 1b, 1e, 2a, 2b, 3a have a strong binding affinity to carbonic anhydrase II. The IC50 values of the four compounds 1e, 2b, 3a, and 3b were lower than that of the positive control drug acetazolamide. What’s more, the compounds had a high inhibitory activity for A549 lung cancer cell growth, among them, 1e and 3a could inhibit both carbonic anhydrase II and lung cancer cell proliferation.